GLP-1 receptor agonists such as semaglutide are changing the way type 2 diabetes and obesity are treated. But these drugs have also shown a surprising ability to improve cardiovascular health — and ...

The drug semaglutide, sold commercially as Ozempic or Wegovy, is well known for helping people lose significant amounts of weight quickly. Now the U.S. Food and Drug Administration has approved Wegovy ...

People who use drugs with anticholinergic effects, including certain antidepressants, drugs for urinary incontinence and common antihistamines, are at higher risk of developing cardiovascular disease.

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. Using two types of cardiovascular drugs together could help to treat ...

Trial results showing that a potent anti-obesity drug offers strong protection against serious heart problems have electrified researchers. They say that the findings could change how this and other ...

Following a rapid increase in popularity of GLP-1 drugs for diabetes and weight loss, such as semaglutide and tirzepatide, approximately one in eight U.S. adults now take these medications, which also ...

Common cardiovascular drugs are linked to a lower risk of dementia in older age, according to a new study. Common cardiovascular drugs are linked to a lower risk of dementia in older age, according to ...

Despite substantial weight loss, most obesity drugs such as Wegovy and Mounjaro do not meaningfully improve quality of life, and few show cardiovascular benefits at one year, according to an analysis ...